Pacira BioSciences, Inc. (PCRX) stock
Close on Nov 17, 2026Market cap $1.45BP/E 104.2Yield –
Pacira BioSciences, Inc. grew revenue 5.7% to $746.16M over the twelve months to Jun 30, 2026. Free cash flow was $179.52M, up 53.3% from a year earlier. At the latest close the market valued the company at $1.45B, 104.2 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.45B
- P/E ratio
- 104.2
- Price to sales
- 1.95
- Price to book
- 2.16
- Dividend yield
- –
- Free cash flow yield
- 12.34%
Fundamentals
- Revenue
- $746.16M
- Net income
- $14.64M
- EPS, diluted
- $0.35
- Free cash flow
- $179.52M
- Book value per share
- $16.67
- Diluted shares
- 40M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $36.48
- Open
- $36.48
- Day's range
- $36.48 – $36.48
- Average volume (20 days)
- 1,070,425
- Index membership
- S&P SmallCap 600, Russell 2000, Russell 3000
- 52-week range
- $18.80 – $36.66
- RSI (14 days)
- 82.9
- Volatility (1 year)
- 56.4%
- Relative volume
- 1.61×
On 2 of our idea lists: Buyback cannibals, Shareholder yield
Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.
| Period | PCRX | S&P 500 | Difference | PCRX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +0.4% | -4.0% | +4.4 pts | ||
| 3 months | +57.0% | -5.0% | +61.9 pts | ||
| Year to date | +41.0% | +8.2% | +32.7 pts | ||
| 1 year | +52.8% | +11.2% | +41.5 pts | ||
| 3 years | +30.8% | +68.5% | −37.7 pts | +9.4% | +19.0% |
| 5 years | -35.8% | +67.3% | −103.0 pts | -8.5% | +10.8% |
| 10 years | -0.2% | +291.6% | −291.8 pts | -0.0% | +14.6% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Pacira BioSciences filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Update
- News
- Results
- Results
About Pacira BioSciences
Pharmaceutical Preparations
Pacira BioSciences develops and commercializes non-opioid pain therapies for patients undergoing surgical procedures or managing chronic joint conditions. The company provides three primary commercial products: EXPAREL, a long-acting injectable local analgesic for postsurgical pain; ZILRETTA, an extended-release corticosteroid injection for osteoarthritis knee pain; and iovera, a handheld cryoanalgesia device that administers targeted cold temperatures to relieve nerve pain without drugs. Its therapies serve surgical patients, including adult and pediatric populations, as well as individuals suffering from osteoarthritis and chronic musculoskeletal pain.
Company profile, executives and historyPacira BioSciences stock: common questions
What is Pacira BioSciences's stock price?
PCRX closed at $36.48 on Nov 17, 2026, up 0.00% on the day. Over the past 52 weeks it traded between $18.80 and $36.66.
What is Pacira BioSciences's market cap?
Pacira BioSciences was worth $1.45B at the close on Nov 17, 2026: the share price times the diluted shares outstanding.
What is PCRX's P/E ratio?
PCRX trades at 104.2 times earnings, based on diluted earnings per share of $0.35 over the twelve months to Jun 30, 2026.
How much revenue does Pacira BioSciences make?
Pacira BioSciences reported revenue of $746.16M for the twelve months to Jun 30, 2026, up 5.7% from a year earlier.
Does Pacira BioSciences pay a dividend?
No. Pacira BioSciences has not paid a cash dividend over the last twelve months.
When does Pacira BioSciences report earnings next?
Pacira BioSciences's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has PCRX stock performed over the past year?
Including dividends, PCRX returned +52.8% over the past year, against +11.2% for the S&P 500.
How many PCRX shares are sold short?
3M shares were sold short at the latest FINRA report, 8.94% of the float, or 3.9 days of average trading volume.
Who are Pacira BioSciences's competitors?
Companies most similar to Pacira BioSciences by business, industry and size include RARE, COLL, ACAD, IONS, MIRM.
See a number that looks wrong?